Melanda Fitriana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melanda Fitriana has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Mun’im
Department of Pharmacognosy-Phytochemistry, Faculty of Pharmacy, Universitas Indonesia, Jl. Kukusan Beji, Depok 16424, Indonesia
1 shared publication Firdayani
Research Center for Vaccine and Drugs, National Research and Innovation Agency (BRIN), South Tangerang-15314, Indonesia
1 shared publication- Hansen Nasif
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia
1 shared publication - Najmiatul Fitria
Universitas Andalas
1 shared publication - Resna Rerita
Bachelor Program. Faculty of Pharmacy. Universitas Andalas. Padang-25163, Indonesia
1 shared publication - Wirawan Adikusuma
Research Center for Computing, Research Organization for Electronics and Informatics, National Research and Innovation Agency, Cibinong, Indonesia
1 shared publication
Latest Publications
- Open Access
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 237-246
EXPLORATION OF THE ACTIVE COMPOUNDS OF MORINGA OLEIFERA LAM AS HIV-1 REVERSE TRANSCRIPTASE INHIBITOR: A NETWORK PHARMACOLOGY AND MOLECULAR DOCKING APPROACH
Objective: This study aims to predict the active compound of Moringa oleifera for the treatment of Human Immunodeficiency Virus (HIV), specifically targeting the HIV-1 reverse transcriptase (HIV-1 RT) enzyme using network pharmacology and molecular docking approach. Methods: The active ingredients of M. oleifera, were screened from the Knapsack database. Subsequently, HIV-1 RT and its related target compounds were retrieved from the Genecard database. The analysis of common targets involved protein-protein interactions (PPI) analysis using string databases and constructing interaction IDs using Cytoscape software. Gene Ontology (GO) functional and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed. Molecular docking studies were conducted using AutoDock Vina software to validate the results of the network pharmacological analysis. Results: A total of 63 active ingredients and 8601 targets related to HIV-1 RT were identified. The network analysis, encompassing GO and KEGG enrichment, revealed strong associations of common targets with key signaling pathways such as Tumor Necrosis Factor (TNF), Toll Like Receptor (TLR), and apoptosis. Additionally, 11 compounds of M. oleifera including apigenin, benzyl isothiocyanate, benzylamine, caffeic acid, ferulic acid, epicatechin, kaempferol, gallic acid, luteolin, syringic acid and vanillin were identified as potential vital compounds. Molecular docking analysis highlighted apigenin and kaempferol as the most promising compounds, exhibiting the lowest binding affinity to the HIV-1 RT enzyme. These compounds correlated with caspase-3(CASP3), caspase-9 (CASP9), and BCL2 Apoptosis Regulator (BAX) protein, stimulating cell apoptosis through multiple pathways. Conclusion: The study highlighted that apigenin and kaempferol are potential compound of M. oleifera in HIV-1 treatment through inhibition activity at HIV-1 RT Enzyme.
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 237-246
Open AccessEXPLORATION OF THE ACTIVE COMPOUNDS OF MORINGA OLEIFERA LAM AS HIV-1 REVERSE TRANSCRIPTASE INHIBITOR: A NETWORK PHARMACOLOGY AND MOLECULAR DOCKING APPROACH
Objective: This study aims to predict the active compound of Moringa oleifera for the treatment of Human Immunodeficiency Virus (HIV), specifically targeting the HIV-1 reverse transcriptase (HIV-1 RT) enzyme using network pharmacology and molecular docking approach. Methods: The active ingredients of M. oleifera, were screened from the Knapsack database. Subsequently, HIV-1 RT and its related target compounds were retrieved from the Genecard database. The analysis of common targets involved protein-protein interactions (PPI) analysis using string databases and constructing interaction IDs using Cytoscape software. Gene Ontology (GO) functional and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed. Molecular docking studies were conducted using AutoDock Vina software to validate the results of the network pharmacological analysis. Results: A total of 63 active ingredients and 8601 targets related to HIV-1 RT were identified. The network analysis, encompassing GO and KEGG enrichment, revealed strong associations of common targets with key signaling pathways such as Tumor Necrosis Factor (TNF), Toll Like Receptor (TLR), and apoptosis. Additionally, 11 compounds of M. oleifera including apigenin, benzyl isothiocyanate, benzylamine, caffeic acid, ferulic acid, epicatechin, kaempferol, gallic acid, luteolin, syringic acid and vanillin were identified as potential vital compounds. Molecular docking analysis highlighted apigenin and kaempferol as the most promising compounds, exhibiting the lowest binding affinity to the HIV-1 RT enzyme. These compounds correlated with caspase-3(CASP3), caspase-9 (CASP9), and BCL2 Apoptosis Regulator (BAX) protein, stimulating cell apoptosis through multiple pathways. Conclusion: The study highlighted that apigenin and kaempferol are potential compound of M. oleifera in HIV-1 treatment through inhibition activity at HIV-1 RT Enzyme.
- Open Access
- 15 February 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 53-57
COST-EFFECTIVENESS OF METFORMIN-GLIMEPIRIDE COMBINATION COMPARED TO SINGLE METFORMIN USE IN DECREASING 2 H POST PRANDIAL BLOOD GLUCOSE
Objective: Complications related to diabetes could reduce the quality of life. In Indonesia, the costs incurred for diabetes mellitus annually will increase as complications of the disease increase. This study explored the cost-effectiveness therapy of metformin-glimepiride combination on post-prandial blood glucose. Methods: Glimepiride is added to the first category for diabetes mellitus receiving metformin to improve blood sugar levels and reduce costs. An observational study was conducted retrospectively to analyze post-prandial blood sugar levels with the total direct medical costs at Universitas Andalas Hospital. The study involved 114 medical records of patients referred during 2021. The combination of Metformin HCL and Glimepiride was compared to Metformin alone in measuring cost and effect parameters. The categorical dependent-independent groups were statistically analyzed using Chi-square, while the cost and effect parameters were calculated to get the Incremental Cost-Effectiveness Ratio (ICER) value. Results: There were no significant differences between groups on sociodemographic characteristics (p<0.05). An incremental cost value of IDR 43,291 was obtained for reducing post-prandial blood sugar by 21.92 mg/dl. Conclusion: Increasing cost and effect parameters require further analysis to determine the trade-off point.
- 15 February 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 53-57
Open AccessCOST-EFFECTIVENESS OF METFORMIN-GLIMEPIRIDE COMBINATION COMPARED TO SINGLE METFORMIN USE IN DECREASING 2 H POST PRANDIAL BLOOD GLUCOSE
Objective: Complications related to diabetes could reduce the quality of life. In Indonesia, the costs incurred for diabetes mellitus annually will increase as complications of the disease increase. This study explored the cost-effectiveness therapy of metformin-glimepiride combination on post-prandial blood glucose. Methods: Glimepiride is added to the first category for diabetes mellitus receiving metformin to improve blood sugar levels and reduce costs. An observational study was conducted retrospectively to analyze post-prandial blood sugar levels with the total direct medical costs at Universitas Andalas Hospital. The study involved 114 medical records of patients referred during 2021. The combination of Metformin HCL and Glimepiride was compared to Metformin alone in measuring cost and effect parameters. The categorical dependent-independent groups were statistically analyzed using Chi-square, while the cost and effect parameters were calculated to get the Incremental Cost-Effectiveness Ratio (ICER) value. Results: There were no significant differences between groups on sociodemographic characteristics (p<0.05). An incremental cost value of IDR 43,291 was obtained for reducing post-prandial blood sugar by 21.92 mg/dl. Conclusion: Increasing cost and effect parameters require further analysis to determine the trade-off point.